A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
← catalyst calendarNCT07428616 · readout in 559 d
Sponsored by Exelixis (industry) · EXEL — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
100estimated
Sites
12
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-21 | actual | When the study began enrolling |
| Primary completion | 2028-02-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Meningioma
Intervention
- Drug: Zanzalintinib — also filed as XL092
Primary outcome
what the primary-completion date above is the date OFObjective Response Rate (ORR) per Response Assessment in Neuro-oncology (RANO) as Assessed by Blinded Independent Central Review (BICR)
measured Up to approximately 12 months
Permalink · EXEL's whole pipeline · Catalyst calendar · Every registered study · What changed